Chugai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chugai Pharmaceutical Co., Ltd.
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Chugai Pharma Europe
- Chugai Pharma Taiwan Ltd.
- C&C Research Laboratories
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.